Standard BioTools Inc (NASDAQ: LAB) started the day on Thursday, with a price increase of 2.46% at $2.91, before settling in for the price of $2.84 at the close. Taking a more long-term approach, LAB posted a 52-week range of $1.46-$3.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -0.06%. Meanwhile, its Annual Earning per share during the time was 8.72%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 61.29%. This publicly-traded company’s shares outstanding now amounts to $383.05 million, simultaneously with a float of $373.22 million. The organization now has a market capitalization sitting at $1.11 billion. At the time of writing, stock’s 50-day Moving Average stood at $2.56, while the 200-day Moving Average is $2.40.
Standard BioTools Inc (LAB) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Diagnostics & Research Industry. Standard BioTools Inc’s current insider ownership accounts for 2.56%, in contrast to 48.33% institutional ownership. According to the most recent insider trade that took place on Mar 05 ’24, this organization’s Director bought 1,403 shares at the rate of 2.62, making the entire transaction reach 3,669 in total value, affecting insider ownership by 11,497,928. Preceding that transaction, on Mar 04 ’24, Company’s Director bought 250,000 for 2.57, making the whole transaction’s value amount to 642,500. This particular insider is now the holder of 11,496,525 in total.
Standard BioTools Inc (LAB) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/30/2023, the organization reported $0 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at $0) by $0. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Standard BioTools Inc’s EPS increase for this current 12-month fiscal period is 61.29% and is forecasted to reach -0.17 in the upcoming year.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Let’s observe the current performance indicators for Standard BioTools Inc (LAB). It’s Quick Ratio in the last reported quarter now stands at 1.26. The Stock has managed to achieve an average true range (ATR) of 0.16. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.48.
In the same vein, LAB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.94, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.17 at the market close of one year from today.
Technical Analysis of Standard BioTools Inc (LAB)
If we take a close look at the recent performances of Standard BioTools Inc (NASDAQ: LAB), its last 5-days Average volume was 4.12 million that shows progress from its year to date volume of 2.13 million. During the previous 9 days, stock’s Stochastic %D was recorded 66.67% While, its Average True Range was 0.16.
Raw Stochastic average of Standard BioTools Inc (LAB) in the period of the previous 100 days is set at 90.04%, which indicates a major rise in contrast to 71.11% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 33.68% that was lower than 62.24% volatility it exhibited in the past 100-days period.
